Skip to main content

Table 1 Characteristics of selected SNPs, and associations between the CHD incidence and SNPs

From: Evaluation of population impact of candidate polymorphisms for coronary heart disease in the Framingham Heart Study Offspring Cohort

       

HR estimates (95% CI)

Closest gene

Gene name

SNP [reference]

Chr

Physical position

Risk allele

MAF

Heterozygous genotype

Homozygous genotype

p-Value

GJA4

gap junction protein, alpha 4

rs618675 [4]

1

34922761

C

0.19

1.32 (1.01, 1.72)

1.73 (1.01, 2.97)

0.0451

PCSK9

proprotein convertase subtilisin/kexin type 9

rs2114580 [4]

1

55167236

A

0.24

1.22 (0.94, 1.59)

1.49 (0.88, 2.54)

0.1376

PSRC1

proline/serine-rich coiled-coil 1

rs599839 [5]

1

109623689

A

0.22

1.05 (0.79, 1.41)

1.11 (0.62, 1.98)

0.7262

MIA3

melanoma inhibitory activity family, member 3

rs17465637 [5]

1

220890152

C

0.29

1.07 (0.82, 1.39)

1.14 (0.67, 1.93)

0.6282

FMN2

formin 2

rs17672135 [6]

1

238512219

C

0.11

1.20 (0.83, 1.73)

1.44 (0.69, 2.99)

0.3286

OR13G1

olfactory receptor, family 13, subfamily G, member 1

rs1151640 [7]

1

245902573

C

0.43

0.98 (0.77, 1.25)

0.96 (0.59, 1.56)

0.8628

  

rs2943634 [5]

2

226776324

C

0.35

1.08 (0.84, 1.39)

1.16 (0.71, 1.92)

0.5508

  

rs10516882 [4]

4

92127599

C

0.17

1.19 (0.85, 1.67)

1.41 (0.72, 2.78)

0.3170

THBS4

thrombospondin 4

rs264986 [4]

5

79206180

T

0.27

1.01 (0.77, 1.32)

1.01 (0.59, 1.74)

0.9656

MTHFD1L

methylenetetrahydrofolate dehydrogenase 1-like

rs6922269 [5]

6

151294678

A

0.27

1.13 (0.87, 1.48)

1.29 (0.76, 2.18)

0.3506

PHACTR1

phosphatase and actin regulator 1

rs1512411 [4]

6

13439076

C

0.34

1.01 (0.78, 1.31)

1.03 (0.61, 1.71)

0.9235

WNT2

wingless-type MMTV integration site family member 2

rs39312 [4]

7

116742021

A

0.35

1.06 (0.83, 1.35)

1.12 (0.68, 1.83)

0.6554

CDKN2A/2B

cyclin-dependent kinase inhibitor 2A/2B

rs1333049 [6]

9

22115503

C

0.48

1.28 (1.01, 1.63)

1.64 (1.02, 2.66)

0.0433

  

rs501120 [5]

10

44073873

C

0.14

0.99 (0.71, 1.39)

0.99 (0.50, 1.94)

0.9681

KIAA0528

KIAA0528

rs10505879 [4]

12

22539123

G

0.22

1.13 (0.86, 1.50)

1.28 (0.74, 2.24)

0.3753

TAS2R50

taste receptor, type 2, member 50

rs1376251 [7]

12

11030119

C

0.33

1.31 (1.00, 1.71)

1.71 (1.01, 2.92)

0.0476

ALOX5AP

arachidonate 5-lipoxygenase-activating protein

rs7984952 [4]

13

30129806

T

0.43

1.24 (0.97, 1.58)

1.54 (0.95, 2.51)

0.0817

  

rs7995384 [4]

13

30177259

T

0.29

1.20 (0.92, 1.57)

1.44 (0.84, 2.48)

0.1830

  

rs117395 [4]

13

30365911

T

0.13

1.09 (0.75, 1.59)

1.19 (0.56, 2.52)

0.6459

SMAD3

SMAD family member 3

rs17228212 [5]

15

65245693

C

0.29

1.04 (0.80, 1.35)

1.08 (0.64, 1.81)

0.7781

  

rs2549513 [4]

16

78108228

C

0.13

1.03 (0.73, 1.47)

1.06 (0.53, 2.15)

0.8617

CDH13

cadherin 13, H-cadherin

rs8055236 [6]

16

81769899

T

0.19

1.26 (0.95, 1.67)

1.59 (0.91, 2.78)

0.1045

SEZ6L

seizure related 6 homolog

rs688034 [6]

22

25019635

C

0.33

1.10 (0.84, 1.43)

1.20 (0.71, 2.04)

0.4971

Risk Scorea

      

1.32 (1.13, 1.54)

 

0.0004

  1. aThe HR estimated the hazard of having incident CHD for one unit increase in the risk score
Back to article page

BMC Proceedings

ISSN: 1753-6561

Contact us